This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Related articles in The Oncologist Similar articles in this journal Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Ryan, D. P. Articles by Lynch, T. J. Search for Related Content PubMed Articles by Ryan, D. P. Articles by Lynch, T. J., Jr.

Reality Testing in Cancer Treatment: The Phase I Trial of Endostatin

The Kenneth B. Schwartz Center at Massachusetts General Hospital, Hematology-Oncology Department, Boston, Massachusetts, USA

Correspondence: Richard T. Penson, M.D., Hematology-Oncology Department, Massachusetts General Hospital Cancer Center, Cox Building, 100 Blossom Street, Boston, Massachusetts 02114-2617, USA. Telephone: 617-726-5857; Fax: 617-726-6974; e-mail: rpenson{at}partners.org

Shortly before his death in 1995, Kenneth B. Schwartz, a cancer patient at Massachusetts General Hospital (MGH), founded The Kenneth B. Schwartz Center at MGH. The Schwartz Center is a non-profit organization dedicated to supporting and advancing compassionate health care delivery which provides hope to the patient, support to caregivers, and encourages the healing process. The center sponsors the Schwartz Center Rounds, a monthly multidisciplinary forum where caregivers reflect on important psychosocial issues faced by patients, their families, and their caregivers, and gain insight and support from fellow staff members.

The September 1999 Schwartz Center Rounds addressed the growing attention around the phase I trial of Endostatin^TM. Endostatin represents a new treatment paradigm. It is an antiangiogenic protein, an endogenous fragment of collagen XVIII. In an attempt to ensure a fair allocation of a very limited number of treatment slots in this classical phase I trial, a lottery was established. More than 1,400 patients enrolled within 2 days of the lottery, all vying for three places in the first cohort. Two contrasting cases are presented, each a potentially eligible patient. The discussion focuses on the dilemma presented by patients desperate for an unproven treatment and the responsibility of staff to explain and support without compounding the hype or suffocating the hope.

Key Words. Endostatin • Phase I • Hype • Hope • Caregivers • Psychosocial

Related articles in The Oncologist:

Reality Testing in Cancer Treatment: The Phase I Trial of Endostatin

David P. Ryan, Richard T. Penson, Sabrina Ahmed, Bruce A. Chabner, and Thomas J. Lynch, Jr.
The Oncologist 1999 4: 501-508. [Abstract] [Full Text]